Sandbox: malabsorption: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 5: Line 5:


{| style="border: 0px; font-size: 100%; margin: 3px;" align="center"
{| style="border: 0px; font-size: 100%; margin: 3px;" align="center"
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" |Cause
! rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |Cause
| colspan="7" align="center" style="background:#4479BA; color: #FFFFFF;" |'''Clinical manifestation'''
| colspan="9" |'''Clinical manifestation'''
! colspan="4" rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" |Lab findings
! colspan="5" rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Lab findings
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" |Additional findings
! rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |Extra intestinal findings
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" |Cause/Pathogenesis
! rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |Cause/Pathogenesis
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" |Gold standard diagnosis
! rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |Gold standard diagnosis
|-
|-
! colspan="6" align="center" style="background:#4479BA; color: #FFFFFF;" |Symptoms
! colspan="8" |Symptoms
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" |Signs
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Signs
|-
|-
! colspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" |Diarrhea
! colspan="2" |Duration
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" |Fever
! colspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Diarrhea
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" |Abdominal pain
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Fever
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" |Weight loss
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Abdominal pain
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Weight loss
!
!
|-
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" |Watery
!Acute
! align="center" style="background:#4479BA; color: #FFFFFF;" |Bloody
!Chronic
! align="center" style="background:#4479BA; color: #FFFFFF;" |Fatty
! style="background:#4479BA; color: #FFFFFF;" align="center" |Watery
! align="center" style="background:#4479BA; color: #FFFFFF;" |WBC
! style="background:#4479BA; color: #FFFFFF;" align="center" |Bloody
! align="center" style="background:#4479BA; color: #FFFFFF;" |Hgb
! style="background:#4479BA; color: #FFFFFF;" align="center" |Fatty
! align="center" style="background:#4479BA; color: #FFFFFF;" |Plt
! style="background:#4479BA; color: #FFFFFF;" align="center" |WBC
! align="center" style="background:#4479BA; color: #FFFFFF;" |Other lab findings
! style="background:#4479BA; color: #FFFFFF;" align="center" |Hgb
! style="background:#4479BA; color: #FFFFFF;" align="center" |Plt
!S/E
! style="background:#4479BA; color: #FFFFFF;" align="center" |Other lab findings
|-
|-
! align="center" style="background:#DCDCDC;" |[[Whipple's disease]]
! style="background:#DCDCDC;" align="center" |[[Whipple's disease]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 44: Line 50:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓/↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓/↑
|
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
*[[Hypoalbuminemia]]
*[[Hypoalbuminemia]]
Line 61: Line 68:
* [[PCR]] testing
* [[PCR]] testing
|-
|-
! align="center" style="background:#DCDCDC;" |[[Celiac disease]]
! style="background:#DCDCDC;" align="center" |[[Celiac disease]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 75: Line 84:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
|
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* [[IgA]] endomysial antibody
* [[IgA]] endomysial antibody
Line 94: Line 104:
* [[IgA]] tissue transglutaminase antibody
* [[IgA]] tissue transglutaminase antibody
|-
|-
! align="center" style="background:#DCDCDC;" |[[Tropical sprue]]
! style="background:#DCDCDC;" align="center" |[[Tropical sprue]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 109: Line 121:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
|
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |  
* [[Vitamin B12 deficiency|Low vitamin B12]]  
* [[Vitamin B12 deficiency|Low vitamin B12]]  
Line 120: Line 133:
* Diagnosis of exclusion
* Diagnosis of exclusion
|-
|-
! align="center" style="background:#DCDCDC;" |[[Crohns disease]]
! style="background:#DCDCDC;" align="center" |[[Crohns disease]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 134: Line 149:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
|
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* [[Iron deficiency]]
* [[Iron deficiency]]
Line 146: Line 162:
* [[Colonoscopy]] with [[biopsy]]
* [[Colonoscopy]] with [[biopsy]]
|-
|-
! align="center" style="background:#DCDCDC;" |[[Ulcerative colitis]]
! style="background:#DCDCDC;" align="center" |[[Ulcerative colitis]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 163: Line 181:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
|
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* Hypoalbuminemia
* Hypoalbuminemia
Line 180: Line 199:
* [[Colonoscopy]] with [[biopsy]]
* [[Colonoscopy]] with [[biopsy]]
|-
|-
! align="center" style="background:#DCDCDC;" |[[Cystic fibrosis]]
! style="background:#DCDCDC;" align="center" |[[Cystic fibrosis]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 194: Line 215:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
|
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* Positive [[DNA]] analysis for [[CFTR]]
* Positive [[DNA]] analysis for [[CFTR]]
Line 206: Line 228:
* Elevated [[Sweat chloride test|sweat chloride]] ≥60 mmol/L
* Elevated [[Sweat chloride test|sweat chloride]] ≥60 mmol/L
|-
|-
! align="center" style="background:#DCDCDC;" |[[VIPoma]]
! style="background:#DCDCDC;" align="center" |[[VIPoma]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 222: Line 246:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
|
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
*Elevated [[VIP]] level
*Elevated [[VIP]] level
Line 239: Line 264:
* Followed by imaging
* Followed by imaging
|-
|-
! align="center" style="background:#DCDCDC;" |[[Zollinger-Ellison syndrome]]
! style="background:#DCDCDC;" align="center" |[[Zollinger-Ellison syndrome]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 251: Line 278:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
|
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |  
* Positive [[secretin]] stimulation test
* Positive [[secretin]] stimulation test
Line 261: Line 289:
* Elevated basal or stimulated serum [[gastrin]]> 120 pg/mL
* Elevated basal or stimulated serum [[gastrin]]> 120 pg/mL
|-
|-
! align="center" style="background:#DCDCDC;" |[[Eosinophilic gastroenteritis]] 
! style="background:#DCDCDC;" align="center" |[[Eosinophilic gastroenteritis]] 
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 273: Line 303:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
|
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |  
* Elevated [[serum]] [[IgE]] levels
* Elevated [[serum]] [[IgE]] levels
Line 286: Line 317:
* [[Eosinophilic]] infiltration of the [[gastrointestinal tract]] on [[biopsy]]
* [[Eosinophilic]] infiltration of the [[gastrointestinal tract]] on [[biopsy]]
|-
|-
! align="center" style="background:#DCDCDC;" |[[Primary bile acid malabsorption]]
! style="background:#DCDCDC;" align="center" |[[Primary bile acid malabsorption]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 298: Line 331:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
|
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |  
* Low  [[Vitamin A|vitamins A]], [[Vitamin D|D]], E, and K  
* Low  [[Vitamin A|vitamins A]], [[Vitamin D|D]], E, and K  
Line 308: Line 342:
* Positive [[SeHCAT]]
* Positive [[SeHCAT]]
|-
|-
! align="center" style="background:#DCDCDC;" |[[Abetalipoproteinemia]]
! style="background:#DCDCDC;" align="center" |[[Abetalipoproteinemia]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 322: Line 358:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
|
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* Low [[triglyceride]]
* Low [[triglyceride]]
Line 335: Line 372:
* Clinical findings and low [[triglyceride]] and [[cholesterol]] level
* Clinical findings and low [[triglyceride]] and [[cholesterol]] level
|-
|-
! align="center" style="background:#DCDCDC;" |[[Microscopic colitis]]
! style="background:#DCDCDC;" align="center" |[[Microscopic colitis]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 347: Line 386:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
|
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* Elevated [[autoantibodies]] include:
* Elevated [[autoantibodies]] include:
Line 366: Line 406:
** [[Lymphocytic]] [[colitis]] is characterized by ≥20 intraepithelial [[lymphocytes]] (IEL) per 100 surface epithelial cells
** [[Lymphocytic]] [[colitis]] is characterized by ≥20 intraepithelial [[lymphocytes]] (IEL) per 100 surface epithelial cells
|-
|-
! align="center" style="background:#DCDCDC;" |[[Hyperthyroidism]]
! style="background:#DCDCDC;" align="center" |[[Hyperthyroidism]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 381: Line 423:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
|
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* Elevated [[T4]]
* Elevated [[T4]]
Line 396: Line 439:
* [[TSH]]
* [[TSH]]
|-
|-
! align="center" style="background:#DCDCDC;" |[[Lactose intolerance]]
! style="background:#DCDCDC;" align="center" |[[Lactose intolerance]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 411: Line 456:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
|
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |  
* [[Hydrogen breath test]]
* [[Hydrogen breath test]]
Line 423: Line 469:
* [[Lactase]] activity assay
* [[Lactase]] activity assay
|-
|-
! align="center" style="background:#DCDCDC;" |[[Irritable bowel syndrome]]
! style="background:#DCDCDC;" align="center" |[[Irritable bowel syndrome]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 437: Line 485:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 443: Line 492:
* Diagnosis of exclusion
* Diagnosis of exclusion
|-
|-
! align="center" style="background:#DCDCDC;" |[[Chronic pancreatitis]]
! style="background:#DCDCDC;" align="center" |[[Chronic pancreatitis]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 454: Line 505:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 460: Line 512:
* [[Secretin]] stimulation test
* [[Secretin]] stimulation test
|-
|-
! align="center" style="background:#DCDCDC;" |[[Cirrhosis]]
! style="background:#DCDCDC;" align="center" |[[Cirrhosis]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 471: Line 525:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 476: Line 531:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
! align="center" style="background:#DCDCDC;" |[[Short bowel syndrome]]
! style="background:#DCDCDC;" align="center" |[[Short bowel syndrome]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 487: Line 544:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 492: Line 550:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Intestinal [[lymphoma]]
! style="background:#DCDCDC;" align="center" |Intestinal [[lymphoma]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 503: Line 563:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 508: Line 569:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
! align="center" style="background:#DCDCDC;" |[[Agammaglobulinemia]]
! style="background:#DCDCDC;" align="center" |[[Agammaglobulinemia]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 519: Line 582:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 524: Line 588:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Intestinal [[lymphangiectasia]]
! style="background:#DCDCDC;" align="center" |Intestinal [[lymphangiectasia]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 535: Line 601:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 540: Line 607:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
! align="center" style="background:#DCDCDC;" |[[Amyloidosis]]
! style="background:#DCDCDC;" align="center" |[[Amyloidosis]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 551: Line 620:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 556: Line 626:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
! align="center" style="background:#DCDCDC;" |[[Mastocytosis]]
! style="background:#DCDCDC;" align="center" |[[Mastocytosis]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 567: Line 639:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 572: Line 645:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
! align="center" style="background:#DCDCDC;" |[[Small intestinal bacterial overgrowth]]
! style="background:#DCDCDC;" align="center" |[[Small intestinal bacterial overgrowth]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 583: Line 658:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 588: Line 664:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Drug induced [[enteritis]]
! style="background:#DCDCDC;" align="center" |Drug induced [[enteritis]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 599: Line 677:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 604: Line 683:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
! align="center" style="background:#DCDCDC;" |[[HIV AIDS|HIV infection]]
! style="background:#DCDCDC;" align="center" |[[HIV AIDS|HIV infection]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 615: Line 696:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 620: Line 702:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
! align="center" style="background:#DCDCDC;" |[[Giardiasis]]
! style="background:#DCDCDC;" align="center" |[[Giardiasis]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 631: Line 715:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 636: Line 721:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
! align="center" style="background:#DCDCDC;" |[[Strongyloidiasis]]
! style="background:#DCDCDC;" align="center" |[[Strongyloidiasis]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 647: Line 734:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 652: Line 740:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
! align="center" style="background:#DCDCDC;" |[[Tuberculosis]]
! style="background:#DCDCDC;" align="center" |[[Tuberculosis]]
|
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 663: Line 753:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
Line 677: Line 768:


{| style="border: 0px; font-size: 100%; margin: 3px;" align="center"
{| style="border: 0px; font-size: 100%; margin: 3px;" align="center"
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" |Cause
! rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |Cause
| colspan="7" align="center" style="background:#4479BA; color: #FFFFFF;" |'''Clinical manifestation'''
| colspan="7" style="background:#4479BA; color: #FFFFFF;" align="center" |'''Clinical manifestation'''
! colspan="4" rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" |Lab findings
! colspan="4" rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Lab findings
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" |Additional findings
! rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |Additional findings
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" |Cause/Pathogenesis
! rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |Cause/Pathogenesis
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" |Gold standard diagnosis
! rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |Gold standard diagnosis
|-
|-
! colspan="6" align="center" style="background:#4479BA; color: #FFFFFF;" |Symptoms
! colspan="6" style="background:#4479BA; color: #FFFFFF;" align="center" |Symptoms
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" |Signs
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Signs
|-
|-
! colspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" |Diarrhea
! colspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Diarrhea
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" |Fever
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Fever
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" |Abdominal pain
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Abdominal pain
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" |Weight loss
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Weight loss
!
!
|-
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" |Watery
! style="background:#4479BA; color: #FFFFFF;" align="center" |Watery
! align="center" style="background:#4479BA; color: #FFFFFF;" |Bloody
! style="background:#4479BA; color: #FFFFFF;" align="center" |Bloody
! align="center" style="background:#4479BA; color: #FFFFFF;" |Fatty
! style="background:#4479BA; color: #FFFFFF;" align="center" |Fatty
! align="center" style="background:#4479BA; color: #FFFFFF;" |WBC
! style="background:#4479BA; color: #FFFFFF;" align="center" |WBC
! align="center" style="background:#4479BA; color: #FFFFFF;" |Hgb
! style="background:#4479BA; color: #FFFFFF;" align="center" |Hgb
! align="center" style="background:#4479BA; color: #FFFFFF;" |Plt
! style="background:#4479BA; color: #FFFFFF;" align="center" |Plt
! align="center" style="background:#4479BA; color: #FFFFFF;" |Other lab findings
! style="background:#4479BA; color: #FFFFFF;" align="center" |Other lab findings
|-
|-
! align="center" style="background:#DCDCDC;" |[[Whipple's disease]]
! style="background:#DCDCDC;" align="center" |[[Whipple's disease]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 733: Line 824:
* [[PCR]] testing
* [[PCR]] testing
|-
|-
! align="center" style="background:#DCDCDC;" |[[Celiac disease]]
! style="background:#DCDCDC;" align="center" |[[Celiac disease]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 766: Line 857:
* [[IgA]] tissue transglutaminase antibody
* [[IgA]] tissue transglutaminase antibody
|-
|-
! align="center" style="background:#DCDCDC;" |[[Tropical sprue]]
! style="background:#DCDCDC;" align="center" |[[Tropical sprue]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 792: Line 883:
* Diagnosis of exclusion
* Diagnosis of exclusion
|-
|-
! align="center" style="background:#DCDCDC;" |[[Crohns disease]]
! style="background:#DCDCDC;" align="center" |[[Crohns disease]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 818: Line 909:
* [[Colonoscopy]] with [[biopsy]]
* [[Colonoscopy]] with [[biopsy]]
|-
|-
! align="center" style="background:#DCDCDC;" |[[Ulcerative colitis]]
! style="background:#DCDCDC;" align="center" |[[Ulcerative colitis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 852: Line 943:
* [[Colonoscopy]] with [[biopsy]]
* [[Colonoscopy]] with [[biopsy]]
|-
|-
! align="center" style="background:#DCDCDC;" |[[Cystic fibrosis]]
! style="background:#DCDCDC;" align="center" |[[Cystic fibrosis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 878: Line 969:
* Elevated [[Sweat chloride test|sweat chloride]] ≥60 mmol/L
* Elevated [[Sweat chloride test|sweat chloride]] ≥60 mmol/L
|-
|-
! align="center" style="background:#DCDCDC;" |[[VIPoma]]
! style="background:#DCDCDC;" align="center" |[[VIPoma]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 911: Line 1,002:
* Followed by imaging
* Followed by imaging
|-
|-
! align="center" style="background:#DCDCDC;" |[[Zollinger-Ellison syndrome]]
! style="background:#DCDCDC;" align="center" |[[Zollinger-Ellison syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 933: Line 1,024:
* Elevated basal or stimulated serum [[gastrin]]> 120 pg/mL
* Elevated basal or stimulated serum [[gastrin]]> 120 pg/mL
|-
|-
! align="center" style="background:#DCDCDC;" |[[Eosinophilic gastroenteritis]] 
! style="background:#DCDCDC;" align="center" |[[Eosinophilic gastroenteritis]] 
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 958: Line 1,049:
* [[Eosinophilic]] infiltration of the [[gastrointestinal tract]] on [[biopsy]]
* [[Eosinophilic]] infiltration of the [[gastrointestinal tract]] on [[biopsy]]
|-
|-
! align="center" style="background:#DCDCDC;" |[[Primary bile acid malabsorption]]
! style="background:#DCDCDC;" align="center" |[[Primary bile acid malabsorption]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 980: Line 1,071:
* Positive [[SeHCAT]]
* Positive [[SeHCAT]]
|-
|-
! align="center" style="background:#DCDCDC;" |[[Abetalipoproteinemia]]
! style="background:#DCDCDC;" align="center" |[[Abetalipoproteinemia]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 1,007: Line 1,098:
* Clinical findings and low [[triglyceride]] and [[cholesterol]] level
* Clinical findings and low [[triglyceride]] and [[cholesterol]] level
|-
|-
! align="center" style="background:#DCDCDC;" |[[Microscopic colitis]]
! style="background:#DCDCDC;" align="center" |[[Microscopic colitis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
Line 1,038: Line 1,129:
** [[Lymphocytic]] [[colitis]] is characterized by ≥20 intraepithelial [[lymphocytes]] (IEL) per 100 surface epithelial cells
** [[Lymphocytic]] [[colitis]] is characterized by ≥20 intraepithelial [[lymphocytes]] (IEL) per 100 surface epithelial cells
|-
|-
! align="center" style="background:#DCDCDC;" |[[Hyperthyroidism]]
! style="background:#DCDCDC;" align="center" |[[Hyperthyroidism]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 1,068: Line 1,159:
* [[TSH]]
* [[TSH]]
|-
|-
! align="center" style="background:#DCDCDC;" |[[Lactose intolerance]]
! style="background:#DCDCDC;" align="center" |[[Lactose intolerance]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 1,095: Line 1,186:
* [[Lactase]] activity assay
* [[Lactase]] activity assay
|-
|-
! align="center" style="background:#DCDCDC;" |[[Irritable bowel syndrome]]
! style="background:#DCDCDC;" align="center" |[[Irritable bowel syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 1,115: Line 1,206:
* Diagnosis of exclusion
* Diagnosis of exclusion
|-
|-
! align="center" style="background:#DCDCDC;" |[[Chronic pancreatitis]]
! style="background:#DCDCDC;" align="center" |[[Chronic pancreatitis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 1,142: Line 1,233:
* [[Endoscopic retrograde cholangiopancreatography|ERCP]]
* [[Endoscopic retrograde cholangiopancreatography|ERCP]]
|-
|-
! align="center" style="background:#DCDCDC;" |[[Cirrhosis]]
! style="background:#DCDCDC;" align="center" |[[Cirrhosis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 1,173: Line 1,264:
* Liver biopsy
* Liver biopsy
|-
|-
! align="center" style="background:#DCDCDC;" |[[Short bowel syndrome]]
! style="background:#DCDCDC;" align="center" |[[Short bowel syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 1,204: Line 1,295:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
! align="center" style="background:#DCDCDC;" |[[Small bowel bacterial overgrowth syndrome|Small bowel bacterial overgrowth]]
! style="background:#DCDCDC;" align="center" |[[Small bowel bacterial overgrowth syndrome|Small bowel bacterial overgrowth]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 1,234: Line 1,325:
* Diagnosis of exclusion
* Diagnosis of exclusion
|-
|-
! align="center" style="background:#DCDCDC;" | '''[[X-linked agammaglobulinemia]]'''
! style="background:#DCDCDC;" align="center" | '''[[X-linked agammaglobulinemia]]'''
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | +
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 1,259: Line 1,350:
* Low circulating immunoglobulin levels (IgG, IgA, IgM, IgE) on blood tests
* Low circulating immunoglobulin levels (IgG, IgA, IgM, IgE) on blood tests
|-
|-
! align="center" style="background:#DCDCDC;" |Intestinal [[lymphangiectasia]]
! style="background:#DCDCDC;" align="center" |Intestinal [[lymphangiectasia]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | -
Line 1,285: Line 1,376:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Intestinal biopsy
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |Intestinal biopsy
|-
|-
! align="center" style="background:#DCDCDC;" |[[Amyloidosis]]
! style="background:#DCDCDC;" align="center" |[[Amyloidosis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,301: Line 1,392:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
! align="center" style="background:#DCDCDC;" |[[Mastocytosis]]
! style="background:#DCDCDC;" align="center" |[[Mastocytosis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,317: Line 1,408:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
! align="center" style="background:#DCDCDC;" |Drug induced [[enteritis]]
! style="background:#DCDCDC;" align="center" |Drug induced [[enteritis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,333: Line 1,424:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
! align="center" style="background:#DCDCDC;" |[[Giardiasis]]
! style="background:#DCDCDC;" align="center" |[[Giardiasis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,349: Line 1,440:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
! align="center" style="background:#DCDCDC;" |[[Strongyloidiasis]]
! style="background:#DCDCDC;" align="center" |[[Strongyloidiasis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
Line 1,365: Line 1,456:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
|-
|-
! align="center" style="background:#DCDCDC;" |[[Tuberculosis]]
! style="background:#DCDCDC;" align="center" |[[Tuberculosis]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |

Revision as of 16:25, 4 December 2017

Malabsorption

Abbreviations: WBC: White blood cells; Plt: Platelets, Hgb: Hemoglobin, IgE: Immunoglobulin E, IgA: Immunoglobulin A

Cause Clinical manifestation Lab findings Extra intestinal findings Cause/Pathogenesis Gold standard diagnosis
Symptoms Signs
Duration Diarrhea Fever Abdominal pain Weight loss
Acute Chronic Watery Bloody Fatty WBC Hgb Plt S/E Other lab findings
Whipple's disease + - + ± + + ↓/↑
Celiac disease ± - ± - + + - -
  • IgA endomysial antibody
  • Anti-tissue transglutaminase antibody
  • Anti-gliadin antibody
  • IgA endomysial antibody
  • IgA tissue transglutaminase antibody
Tropical sprue + - + + + + - -
  • Diagnosis of exclusion
Crohns disease + + + + + +
  • Abnormal immune response to self antigens
Ulcerative colitis + + + + + +
  • Hypoalbuminemia
  • Hypokalemia
  • Hypomagnesemia
  • Iron deficiency
  • Elevated ESR
  • Elevated CRP
  • Abnormal immune response to self antigens
Cystic fibrosis - - + ± + + - -
  • Positive DNA analysis for CFTR
  • Evaluated nasal transepithelial potential difference (NPD)
VIPoma + - + - + + - - -
  • Primary secretory tumor
  • Elevated VIP levels
  • Followed by imaging
Zollinger-Ellison syndrome + - + - + + - -
  • Elevated basal or stimulated serum gastrin> 120 pg/mL
Eosinophilic gastroenteritis  + - + - + + - -
Primary bile acid malabsorption + - + - + + - -
Abetalipoproteinemia + - + - + + - - -
Microscopic colitis + + - - + + - -
Hyperthyroidism + - - ± + + - - -
  • Elevated T4
  • Elevated T3
  • Decreased TSH
Lactose intolerance + - - - + - - - -
Irritable bowel syndrome ± - ± - ± - - - -
  • Diagnosis of exclusion
Chronic pancreatitis + - + - + +
Cirrhosis + - + + + +
Short bowel syndrome -
Intestinal lymphoma
Agammaglobulinemia
Intestinal lymphangiectasia
Amyloidosis
Mastocytosis
Small intestinal bacterial overgrowth
Drug induced enteritis
HIV infection
Giardiasis
Strongyloidiasis
Tuberculosis

Chronic diarrhea

Abbreviations: WBC: White blood cells; Plt: Platelets, Hgb: Hemoglobin, IgE: Immunoglobulin E, IgA: Immunoglobulin A

Cause Clinical manifestation Lab findings Additional findings Cause/Pathogenesis Gold standard diagnosis
Symptoms Signs
Diarrhea Fever Abdominal pain Weight loss
Watery Bloody Fatty WBC Hgb Plt Other lab findings
Whipple's disease + - + ± + + ↓/↑
Celiac disease ± - ± - + + - -
  • IgA endomysial antibody
  • Anti-tissue transglutaminase antibody
  • Anti-gliadin antibody
  • IgA endomysial antibody
  • IgA tissue transglutaminase antibody
Tropical sprue + - + + + + - -
  • Diagnosis of exclusion
Crohns disease + + + + + +
  • Abnormal immune response to self antigens
Ulcerative colitis + + + + + +
  • Hypoalbuminemia
  • Hypokalemia
  • Hypomagnesemia
  • Iron deficiency
  • Elevated ESR
  • Elevated CRP
  • Abnormal immune response to self antigens
Cystic fibrosis - - + ± + + - -
  • Positive DNA analysis for CFTR
  • Evaluated nasal transepithelial potential difference (NPD)
VIPoma + - + - + + - - -
  • Primary secretory tumor
  • Elevated VIP levels
  • Followed by imaging
Zollinger-Ellison syndrome + - + - + + - -
  • Elevated basal or stimulated serum gastrin> 120 pg/mL
Eosinophilic gastroenteritis  + - + - + + - -
Primary bile acid malabsorption + - + - + + - -
Abetalipoproteinemia + - + - + + - - -
Microscopic colitis + + - - + + - -
Hyperthyroidism + - - ± + + - - -
  • Elevated T4
  • Elevated T3
  • Decreased TSH
Lactose intolerance + - - - + - - - -
Irritable bowel syndrome ± - ± - ± - - - -
  • Diagnosis of exclusion
Chronic pancreatitis + - + - + + - - -
  • Slightly elevated amylase and lipase
  • Abnormal pancreatic function test
  • Repeated acute pancreatitis
  • Alcohol abuse
  • Genetic
  • Autoimmune
Cirrhosis + - + + + +
  • Jaundice
  • Hepatosplenomegaly
  • Abdominal distention
  • Shifting dullness
  • Asterixis
  • Skin telangiectasias 
  • Abnormal liver function tests
  • Prolonged PT/PTT
  • Coagulopathy
  • Portal hypertension
  • Hepatic encephalopathy
  • Liver biopsy
Short bowel syndrome + - + - - + -
  • Prior intestinal surgery
  • Surgical intestinal resection
Small bowel bacterial overgrowth + - + - + + - -
  • Excess bacteria in the small intestine
  • Alterations in intestinal anatomy or GI motility, 
  • Lack of gastric acid secretion
  • Diagnosis of exclusion
 X-linked agammaglobulinemia + - + + + +
  • Signs of dehydration
  • Signs of infections
-
  • Hypogammaglobulinemia
  • Recurrent respiratory tract infections
  • Gastroenteritis
  • Bacterial infections
  • Malabsorption
  • Inherited Gene defect 
  • Low circulating immunoglobulin levels (IgG, IgA, IgM, IgE) on blood tests
Intestinal lymphangiectasia - - + - - +
  • Peripheral edema
  • Macular edema 
- -
  • Hypoproteinemia
  • Hypogammaglobulinemia
  • Protein-losing enteropathy
  • Malabsorption
  • Anergy
  • Homograft rejection
  • Pachydermoperiostosis 
  • Dilatation of intestinal lymphatics
Intestinal biopsy
Amyloidosis +
Mastocytosis
Drug induced enteritis
Giardiasis +
Strongyloidiasis
Tuberculosis
Chronic laxative abuse